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Acinetobacter baumannii is an important opportunistic pathogen associated with
a variety of nosocomial infections. A rapid and sensitive molecular detection in
clinical isolates is quite needed for the appropriate therapy and outbreak control of
A. baumannii. Group 2 carbapenems have been considered the agents of choice
for the treatment of multiple drug-resistant A. baumannii. But the prevalence of
carbapenem-resistant A. baumannii (CRAB) has been steadily increasing in recent years.
Here, we developed a loop-mediated isothermal amplification (LAMP) assay for the
rapid detection of A. baumannii in clinical samples by using high-specificity primers
of the blaOXA−51 gene. Then we investigated the OXA-carbapenemases molecular
epidemiology of A. baumannii isolates in two comprehensive hospitals in Beijing. The
results showed that the LAMP assay could detect target DNA within 60 min at 65◦C.
The detection limit was 50 pg/μl, which was about 10-fold greater than that of
PCR. Furthermore, this method could distinguish A. baumannii from the homologous
A. nosocomialis and A. pittii. A total of 228 positive isolates were identified by this LAMP-
based method for A. baumannii from 335 intensive care unit patients with clinically
suspected multi-resistant infections in two hospitals in Beijing. The rates of CRAB are
on the rise and are slowly becoming a routine phenotype for A. baumannii. Among
the CRABs, 92.3% harbored both the blaOXA−23 and blaOXA−51 genes. Thirty-three
pulsotypes were identified by pulsed-field gel electrophoresis, and the majority belonged
to clone C. In conclusion, the LAMP method developed for detecting A. baumannii was
faster and simpler than conventional PCR and has great potential for both point-of-
care testing and basic research. We further demonstrated a high distribution of class D
carbapenemase-encoding genes, mainly OXA-23, which presents an emerging threat
in hospitals in China.
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Introduction
Acinetobacter baumannii is an important opportunistic pathogen
associated with a variety of nosocomial infections, such
as ventilator-associated pneumonia, central line-associated
bloodstream infections, urinary tract infections, surgical-site
infections, and other types of wound infections, especially in
intensive care units (ICUs; Peleg et al., 2008). This organism
is well adapted to hospital environments, being capable of
continually spreading to new patients and making itself a
nosocomial pathogen of particular clinical concern and a public
health threat (Dijkshoorn et al., 2007).
In recent years, multidrug-resistant A. baumannii (MDR-
AB) isolates have been increasingly reported worldwide.
MDR-AB strains are associated with an enhanced risk of
mortality and prolonged durations of hospitalization (Kempf
and Rolain, 2012; Antunes et al., 2014; Lemos et al., 2014).
Carbapenems, mainly imipenem (IPM) andmeropenem (MPM),
have been used to treat MDR-AB infections (Perez et al.,
2007). However, the incidence of carbapenem resistance in
A. baumannii is growing steadily in China and many other
countries (Poirel and Nordmann, 2006; Tiwari et al., 2012a,b).
According to the CHINET 2010 year reports, the resistant
to IPM and MPM in A. baumannii isolates was 62.3% and
63.8%, respectively (Xi et al., 2012). However, few data are
available regarding the molecular epidemiology and antibiotic
resistance of A. baumannii infections in hospitals in Beijing,
China.
The accurate and rapid identiﬁcation of A. baumannii is
critical for appropriate infection control in hospital settings.
To date, the most common and widespread detection methods
include characterization via a phenotypic system and commercial
phenotypic methods (e.g., the VITEK 2 system [Biomerieux]
and the API 20 NE system) or DNA-based testing such as
PCR (e.g., 16S rRNA gene ampliﬁcation), which have been used
to successfully identify most Acinetobacter species. However,
there are some limitations in these methods (Janda and
Abbott, 2007; Karah et al., 2011; Álvarez-Buylla et al., 2012).
For example, several days are needed for incubation, and
the laboratory diagnosis of A. baumannii is actually for that
of the A. calcoaceticus–A. baumannii complex (ABC), which
includes A. calcoaceticus, A. baumannii, A. pittii (three species),
and A. nosocomialis (species 13TU; Peleg et al., 2008). These
bacterial species are diﬀerent in terms of symptomatology,
dissemination patterns, mechanisms of antibiotic resistance, and
epidemiology (Golanbar et al., 2011; Chiang et al., 2012).
The loop-mediated isothermal ampliﬁcation (LAMP)method,
which is based on autocycling strand displacement DNA
synthesis in the presence of Bst DNA polymerase, can be used to
amplify target DNA with high speciﬁcity (as four or six speciﬁc
primers that recognize six or eight diﬀerent sequences on the
DNA target) under isothermal conditions in less than 60 min
(Notomi et al., 2000). LAMP is highly sensitive and able to detect
DNA at as few as six copies in the reaction mixture, and less
prone to the presence of irrelevant DNA than PCR (Notomi
et al., 2000). This novel method has been developed widely
for the detection of numerous pathogens, including inﬂuenza
A subtypes H1N1 (Nakauchi et al., 2011), H5N1 (Dinh et al.,
2011), H7N9 (Nakauchi et al., 2014), as well as Mycoplasma
pneumoniae (Gotoh et al., 2013), Mycobacterium tuberculosis
(Kumar et al., 2014), severe acute respiratory syndrome virus
coronavirus (Poon et al., 2004), and human immunodeﬁciency
virus (Zeng et al., 2014).
In present study, we describe a LAMP method for the rapid
detection of A. baumannii in clinical samples targeting the
blaOXA−51 gene, which was based on visual testing. We also
investigated molecular-epidemiology and antibiotic-resistance
proﬁles, and detected several common oxacillinase genes from
A. baumannii isolates obtained at two comprehensive hospitals
in Beijing, China.
Materials and Methods
Bacterial Strains, Antimicrobial Susceptibility
Testing, and Pulsed-Field Gel Electrophoresis
(PFGE)
A total of 34 strains representing 9 Acinetobacter species (2
A. baumannii strains and 10 other Acinetobacter strains) and
22 non-Acinetobacter species used in this study to develop
the LAMP assays. Three hundred and ﬁfty-ﬁve clinical sputum
samples and nasopharyngeal swabs were obtained from the ICU
hospitalized patients with clinically suspected multi-resistant
infections in 307th (Aﬃliated Hospital of Academy of Military
Medical Sciences), and the 309th Hospital of PLA in China.
Pertinent information and the source of all strains are listed
in Table 1. The species identiﬁcation were identiﬁed by the
Vitek 2 system (Biomerieux Vitek, Inc., Hazelwood, MO, USA).
A. baumannii bacteria were grown overnight at 37◦C in
Luria-Bertani (LB) broth, while non-Acinetobacter species were
cultured at 37◦C in brain heart infusion (BHI) broth overnight.
Antibiotic susceptibility testing was conducted by disk
diﬀusion in accordance with the guidelines of the Clinical
and Laboratory Standards Institute and was conﬁrmed
by the Vitek 2 System with the following antibiotics:
ampicillin, ampicillin/sulbactam, aztreonam, ciproﬂoxacin,
ceftazidime, ceftriaxone, cefepime, gentamycin, levoﬂoxacin,
IPM, MPM, piperacillin/tazobactam, piperacillin, tobramycin,
and sulfamethoxazole. Pseudomonas aeruginosa ATCC 27853
was used as a control.
Genomic DNA was prepared in agarose plugs, and digested
with the restriction enzymeApaI (New England BioLabs, Beverly,
MA, USA). The DNA restriction fragments were separated using
a CHEF-DRIII apparatus (Bio-Rad Laboratories, Richmond, CA,
USA). Gel images were analyzed using BioNumerics software,
version 6.01 (Applied-Maths, Belgium). The interpretation of gels
was performed by visual inspection using the criteria of Tenover
et al. (1995).
Preparation of Isolated DNA
Genomic DNA from Acinetobacter species was prepared using
the boiling method described by Olive and Bean (1999), with
some modiﬁcations. Brieﬂy, colonies of each isolate were picked
from LB plates and suspended in 100 μl of ddH2O. The bacterial
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TABLE 1 | Bacteria strains used in this study.
Bacteria strains Source Strain type
Acinetobacter species
A. baumannii CGMCC Reference strain
A. baumannii ATCC 22933 CICC Reference strain
A. calcoaceticus CGMCC Reference strain
A. nosocomialis CGMCC Reference strain
A. haemolyticus CGMCC Reference strain
A. Pittii CICC Reference strain
A. johnsonii CGMCC Reference strain
A. junii CGMCC Reference strain
A. calcoaceticus The Microorganism Centera Reference strain
A. lwoffii The Microorganism Center (three strains) Reference strain
Non-Acinetobacter species
Bacillus megatherium 4623 The Microorganism Center Reference strain
Beta-haemolytic streptococcus group A CMCC32213 The Microorganism Center Reference strain
Bordetella pertussis ATCC 18530 The Microorganism Center Reference strain
Brucella suis 3572 The Microorganism Center Reference strain
Corynebacterium diphtheria CMCC38001 The Microorganism Center Reference strain
Enteropathogenic Escherichia coli 2348 The Microorganism Center Reference strain
Enterotoxigenic E. coli 44824 The Microorganism Center Reference strain
E. coli ATCC25922 The Microorganism Center Reference strain
Mycobacterium tuberculosis 8362 The Microorganism Center Reference strain
Neisseria meningitides group B CMCC29022 The Microorganism Center Reference strain
Pseudomonas aeruginosa ATCC27853 The Microorganism Center Reference strain
Salmonella aberdeen 9264 The Microorganism Center Reference strain
Salmonella enteritidis 50326-1 The Microorganism Center Reference strain
Stenotrophomonas maltophilia 3859 The Microorganism Center Reference strain
Shigella flexneri 4536 The Microorganism Center Reference strain
Shigella sonnei 2531 The Microorganism Center Reference strain
Staphylococcus aureus 2740 The Microorganism Center Reference strain
Vibrio carchariae 5732 The Microorganism Center Reference strain
Vibrio cholera 3802 The Microorganism Center Reference strain
Vibrio parahaemolyticus 5474 The Microorganism Center Reference strain
Yersinia enterocxolitica 1836 The Microorganism Center Reference strain
Yersinia pestis 2638 The Microorganism Center Reference strain
CGMCC, China General Microbiological Culture Collection Center; CICC, China Center of Industrial Culture Collection.
aThe Microorganism Center of the Institute of Disease Control and Prevention of the Academy of Military Medical Sciences.
suspensions were boiled at 95◦C for 15 min, centrifuged at
12,000 rpm for 5 min, and the supernatants were collected
and transferred to fresh Eppendorf tubes as templates for use
in LAMP and PCR assays. To determine the sensitivity and
speciﬁcity of the LAMP assays, bacterial genomic DNA was
extracted from A. baumannii using the Wizard R© Genomic DNA
Puriﬁcation Kit A1125 (Promega, Madison, WI, USA). The DNA
concentration was measured by using OD260 measurements
(ND-1000 spectrophotometer, NanoDrop Technologies, Inc,
Wilmington, DE, USA) and prepared by serial 10-fold dilutions
to yield concentrations ranging from 500 ng/μl to 0.05 pg/μl.
Primer Design for LAMP Assay
The sequence of blaOXA−51 (GenBank No. DQ385606.1) was
downloaded from the NCBI GenBank database and used to
design blaOXA−51-speciﬁc LAMP primers. The sequence was
further analyzed by Primer Explorer software (version 4;
http://www.primerexplorer.jp/lamp/), and ﬁve sets of primers
were designed, including the outer forward primer (F3), the
outer backward primer (B3), the forward inner primer (FIP), the
backward inner primer (BIP), and additional loop primers (loops
F and B), as shown in Table 2.
LAMP Reaction and Product Detection
LAMP reactions were performed in a total volume of 25 μl and
contained 12.5 μl reaction mixtures (DNA Ampliﬁcation Kit;
Eiken Chemical Co., Ltd., Tochigi, Japan), 2.6 μl primer mixture
(40 pmol for FIP and BIP, 20 pmol for LF and LB, and 5 pmol for
F3 and B3), and 1μl of Bst polymerase (eight units, New England
BioLabs, Ipswich, MA, USA). Finally, 1-μl DNA of genomic
template DNA (the concentration is above 50 ng/μl) was added
to the reaction tubes. Reaction was performed in a LA-320CE
instrument (Eiken Chemical Co., Ltd., Tochigi, Japan) at 65◦C
for 60 min and stopped by heating to 80◦C for 5 min, according
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TABLE 2 | Sequence of primers used for specific amplification of
blaOXA−51−like and the OXA carbapenemases PCR detection.
Primer Primer type Sequence (5′–3′ )
OXA-4F3 Forward outer CTTATATAGTGACTGCTAATCCAA
OXA-4B3 Backward outer ATTAAGCATTTTGAAGGTCGA
OXA-4FIP Forward inner ACCCGTAGTGTGTACTTCGTTAA
ATTTTTACAGCGCTTCAAAATCTGA
OXA-4BIP Backward inner TTAGTTATCCAACAAGGCCAAACTT
TTTAGCAGGTACATACTCGGTC
OXA-4LB Loop forward AAAGCTATGGTAATGATCTTGCTCG
blaOXA−23−F Forward ATGAATAAATATTTTACTTG
blaOXA−23−R Reverse TTAAATAATATTCAGCTGTT
blaOXA−24−F Forward ATGAAAAAATTTATACTTCCT
ATATTCAGC
blaOXA−24−R Reverse TTAAATGATTCCAAGATTTTCTAGC
blaOXA−51−like−F Forward TAATGCTTTGATCGGCCTTG
blaOXA−51−like−R Reverse CTATAAAATACCTAATTKTTCTAA
blaOXA−58−F Forward ATGAAATTATTAAAAATATTGAGT
blaOXA−58−R Reverse ATAAATAATGAAAAACACCCAA
to the manufacturer’s instructions. The LA-320CE instrument
can monitor the turbidity of real-time LAMP products through
spectrophotometric analysis by recording the optical density
at 650 nm every 6 s with the help of a Loopamp real-time
turbidimeter. In addition, a visual color-change detectionmethod
was employed. Brieﬂy, 1 μl of ﬂuorescence-detection reagent
(Eiken Chemical Co., Ltd., Tochigi, Japan) was added to each
25 μl LAMP-reaction mixture prior to initiating the reactions.
Positive reactions were identiﬁed by a green color change, while
negative reactions remained orange in color. The color change
could be observed by the naked eye under natural light, or with
the aid of ultraviolet light excitation at 365 nm.
To compare the sensitivity and speciﬁcity of LAMP with
PCR, normal PCR reactions were performed using the
blaOXA−51−like−F and blaOXA−51−like−R primers (Table 2).
The primers were synthesized commercially by Sangon Biotech
Co., Ltd. (Beijing, China). PCR was performed as described
previously (Kuo et al., 2012).
PCR Detection of Carbapenemase Genes
The class D OXA carbapenemases of Acinetobacter sp. are
represented by 4 main phylogenetic subgroups: OXA-23-like,
OXA-24-like, OXA-51-like, and OXA-58. The primers used for
detecting these genes by PCR are listed in Table 2. PCR was
performed in a 25-μl reaction mixtures containing 12.5 μl PCR
Master Mix Reagent (Tiangen Biotech Co., Ltd., Beijing, China);
1 μl of forward primer (10 pmol), 1 μl of reverse primer
(10 pmol), and 1 μl of DNA template. Reaction mixtures were
initially heated to 94◦C for 5 min, followed by 30 cycles at 94◦C
for 30 s, 55◦C for 30 s, and 72◦C for 90 s. The ﬁnal extension step
was performed at 72◦C for 7 min. The PCR-ampliﬁed products
were analyzed by 1% agarose gel electrophoresis and stained with
ethidium bromide. Images were acquired using a Bio-Rad Gel
Doc EQ imaging system.
Results
Optimization of the LAMP Assay Targeting
blaOXA−51−like
Five sets of diﬀerent primers were initially tested for detection
of the blaOXA−51−like gene, and the primers for pgaD gene of
A. baumanniiwere added as a control (Wang et al., 2013). Four of
the ﬁve primer sets enabled successful ampliﬁcation (Figure 1).
The OXA-4 primer set ampliﬁed the target sequence within the
shortest time and was, therefore, chosen as the optimal primer
set (Table 2).
Reaction temperatures ranging from 55 to 69◦C at a 2◦C
intervals were compared to determine optimal ampliﬁcation
conditions. The ampliﬁcation eﬃciency was highest at 65◦C
(Figure 2) and was, therefore, used in subsequent experiments.
FIGURE 1 | Five sets of primers were used to amplify the indicated target genes of Acinetobacter baumannii under the same conditions. Turbidity was
monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s. The OXA-4 primer set was chosen as the most appropriate
primers for the rapid detection of A. baumannii.
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FIGURE 2 | Effect of differing temperatures on the efficiency of detection of A. baumannii by loop-mediated isothermal amplification (LAMP). Turbidity
was monitored using a Loopamp real-time turbidimeter by measuring the absorbance at 650 nm every 6 s.
Specificity and Sensitivity of the LAMP Assay
To evaluate the speciﬁcity of LAMP detection for A. baumannii,
genomic DNA was extracted from 2 A. baumannii strains,
as well as other 7 Acinetobacter species (10 strains) and 22
non-A. baumannii reference strains, and tested using real-
time turbidity or visual detection of color changes as readouts.
Genomic A. baumannii DNA (ATCC 22933) and distilled water
were used as positive and negative controls, respectively. As
shown in Figure 3, both methods of analysis positively identiﬁed
the A. baumannii isolates. All other strains (as well as the blank
control) tested negatively, indicating that the LAMP assay was
speciﬁc for A. baumannii. Interestingly, the LAMP assay could
diﬀerentiate A. baumannii from other Acinetobacter species.
To compare the detection limit of traditional PCR with
that of LAMP using either real-time turbidity or color-change
measurements, 10-fold serial dilutions (50 ng/μl–5 pg/μl) were
tested using genomic DNA extracted from A. baumannii ATCC
22933. As shown in Figure 4, the detection limits of real-time
turbidity and visual detection were both 50 pg/μl, which was
10-fold more sensitive than traditional PCR assay.
Detection of A. baumannii in Clinical Samples
A total of 355 clinical sputum samples and nasopharyngeal swabs
were collected for LAMP-based surveillance of blaOXA−51−like
from ICU patients suspected of having multidrug-resistant
infections in two hospitals in Beijing, China. Ten pairs of sputum
samples and nasopharyngeal swabs from healthy people were
collected as controls. All clinical samples were simultaneously
analyzed by LAMP and PCR. Of the 355 clinical samples, the
LAMP assay detected 228 positive samples and 127 negative
samples, while the PCR assay detected 221 positive samples,
and 134 negative samples. Then, A. baumannii was successfully
cultured from all 228 samples that were positively identiﬁed
by LAMP. Samples from the healthy control subjects all tested
negatively by LAMP and PCR. The LAMP assay showed 100%
speciﬁcity compared to 91.89% by PCR assay. Thus, the results
FIGURE 3 | Specificity of the LAMP reactions in detecting the blaOXA−51−like gene. Turbidity was monitored using a Loopamp real-time turbidimeter by
measuring the absorbance at 650 nm every 6 s. Amplification was performed at 65◦C for 60 min.
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FIGURE 4 | Sensitivity of the LAMP reaction and PCR for detection of
the blaOXA−51−like gene. Genomic DNA was diluted in a set of serial 10-fold
dilutions. Both LAMP reactions (A,B) and PCR (C) were performed in
duplicate for each dilution. Tubes and lanes: 1: 500 ng/μl, 2: 50 ng/μl, 3:
5 ng/μl, 4: 500 pg/μl, 5: 50 pg/μl, 6: 5 pg/μl, 7: 0.5 pg/μl, 8: 0.05 pg/μl.
(A) Turbidity was monitored using a Loopamp real-time turbidimeter by
measuring the absorbance at 650 nm every 6 s. (B) The direct visual method
for the detection of LAMP. One microliter of fluorescent detection reagent was
added to 25 μl of LAMP reaction mixture before the LAMP reactions were
initiated. (C) PCR products were separated by 1% agarose gel
electrophoresis and stained with ethidium bromide.
showed the LAMP assays were more sensitive and speciﬁc than
PCR for the diagnosis of A. baumannii in clinical samples.
Antibiotic Susceptibility and Oxacillinase
Distribution
A total of 228 clinical A. baumannii isolates were characterized by
antibiotic susceptibility testing using both the VITEK R©2 system
and disk diﬀusion. Resistance rates were very high, with nearly
90% isolates being resistant to ampicillin, 68.2% being MDR-AB,
66.5% being resistant to IPM, and 63.6% being resistant to MPM.
Among all 145 isolates resistant to both IPM and MPM,
100% harbored the blaOXA−51−like gene, 92.3% (134 strains) co-
occurred with the blaOXA−23 gene, 1 isolate carrying both the
blaOXA−51−like gene and blaOXA−58 gene, and no isolate carried
the blaOXA−24 gene. Ten isolates were negative for the tested
plasmid-mediated OXA-carbapenemase genes.
We also investigated the presence of the blaOXA−51−like gene
inA. baumannii isolates susceptible to carbapenem treatment. All
of these isolates harbored the naturally occurring blaOXA−51−like
gene, making it an excellent candidate for the identiﬁcation of
Acinetobacter species.
Molecular Epidemiology of
Carbapenem-Resistant A. baumannii
Forty-one out of 145 carbapenem-resistant A. baumannii isolates
were analyzed by PFGE. Genomic DNA digested with ApaI
showing similar patterns were designated as the same type,
and those with 1–3 diﬀerent bands compared with this type
were designated as subtypes. Digested DNA with >3 diﬀerent
bands compared with one type were designated as other types.
Bionumerisc software V6.01 was used to perform cluster analysis
of these data.
A total of 33 PFGE-banding types were identiﬁed, suggesting
a diverse population of A. baumannii rather than the spread of a
speciﬁc clone. According to the dice similarity index (80%), these
types could be clustered into eight distinct PFGE patterns (clones
A–H), and clone C was the dominant clone with 24 isolates
(Figure 5). Clinical isolates with PFGE-banding type 18 (PF-18)
represented the dominant epidemic strain in the ICU during the
testing period.
Discussion
Carbapenems including IPM and MPM are used as a last resort
for treating MDR-AB. The incidence of carbapenem resistance
in A. baumannii has increased steadily over the past decade
and now represents a global problem. The Meropenem Yearly
Susceptibility Test Information Collection program revealed a
considerable worldwide increase in IPM and MPM resistance
rates, which increased from 10 and 35% in 1999 to 47.9 and 57.4%
in 2008, respectively (Rhomberg and Jones, 2009). Similarly,
the SENTRY program documented an overall increase in IPM
resistance from 34.5% in 2006 to 59.8% in 2009 (Gales et al.,
2011). In the USA and Europe, carbapenem resistance accounted
for 65% of A. baumannii-related pneumonia in 2012 (Farrell
et al., 2014). In Asia, more than 60% of A. baumannii isolates
causing hospital-acquired pneumonia were pan-resistant bacteria
and resistant to carbapenem (Zarrilli et al., 2013; Tiwari and
Moganty, 2014).
In this study, we observed that 66.5% (152 strains) or 63.6%
(145 strains) of test isolates were resistant to IPM or MPM,
respectively. The 228 clinical A. baumannii isolates were mainly
collected from the ICUs of two hospitals; thus, the incidence
of carbapenem resistance in A. baumannii was relatively high.
Prolonged hospitalization, invasive medical procedures, and
the prior use of broad-spectrum antibiotics (third-generation
cephalosporins and ﬂuoroquinolones) are risk factors for the
acquisition of MDR-AB (Karageorgopoulos and Falagas, 2008).
These ﬁndings indicated that treatment with carbapenem may
potentially induce carbapenem resistance.
During PFGE analysis, 33 PFGE-banding patterns were
identiﬁed and classiﬁed into 8 distinct clones, based on Tenover’s
criteria (Tenover et al., 1995). Clone C was the dominant
clone, making it possibly responsible for the A. baumannii
epidemic in the ICUs of the two comprehensive hospitals
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FIGURE 5 | Pulsed-field gel electrophoresis (PFGE) of Apa I-digested DNA from 41 A. baumannii isolates. The dendrogram shown was generated via the
unweighted pair-group method using arithmetic averages approach, based on Dice similarity coefficients that were determined using BioNumerics software, V6.01.
from which we obtained the isolates. Clinical isolates of
subtype PF-18 represented the main epidemic strain during
the testing period. Previous results have demonstrated that
carbapenem-resistant A. baumannii isolates showing the same
PFGE patterns possess the same carbapenemase-associated genes
(Yan et al., 2010; Park et al., 2012); however, our results were
not consistent with these observations. Three isolates carrying
only the blaOXA−51−like gene, but not the blaOXA−23 gene, were
grouped into diﬀerent clones. However, isolates carrying both
the blaOXA−51−like gene and the blaOXA−23 gene were clustered
into distinct clones, either. This may be due to the complicated
resistance mechanism that underlies carbapenem resistance in
A. baumannii.
Carbapenem susceptibility in A. baumannii is compromised
by a variety of mechanisms. By far the most common mechanism
are carbapenemases (Pogue et al., 2013). Carbapenem-
hydrolyzing class D β-lactamases (CHDLs, Ambler class
D), also known as oxacillinases, are the most common
mediator of carbapenem resistance in A. baumannii (Poirel
and Nordmann, 2006), although they are relatively ineﬃcient
compared with other types of carbapenemases, such as class B
metallo-β-lactamases (MBLs; Ambler class B) represented by the
VIM, IMP, SIM families, and the recently discovered New Delhi
metallo-β-lactamase (NDM).
Among CHDLs in A. baumannii, there are four major
distinct groups, including OXA-23, OXA-24, OXA-51-like, and
OXA-58, which are encoded by the blaOXA−23, blaOXA−24,
blaOXA−51−like, and blaOXA−58 genes, respectively (Poirel and
Nordmann, 2006; Zavascki et al., 2010). The blaOXA−23 gene
has been reported in A. baumannii isolates worldwide and
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is mediated both by chromosomal integration and plasmids.
The blaOXA−24 gene can also be localized to chromosomes or
plasmids, appears to be less widespread than the blaOXA−23
gene, and is relatively rare in China (Poirel et al., 2010).
The chromosomally located blaOXA−51−like gene is unique and
naturally occurring in A. baumannii; thus, this gene is becoming
an important genetic marker for the identiﬁcation of organisms
at the species level (Turton et al., 2006, ). The plasmid-mediated
blaOXA−58 gene has been reported in Acinetobacter sp. from
many countries around the world, but is rare in China.
In this research, we found that in all the 145 CRAB isolates,
the co-occurrence of blaOXA−51−like gene and blaOXA−23 gene
could be detected in 134 isolates (92.3%). This result indicated
that the plasmid-mediated transfer of blaOXA−23 gene might
be the most common mechanism by which A. baumannii
becomes carbapenem resistance in these two comprehensive
military hospitals in Beijing. Although the blaOXA−58 gene and
blaOXA−24 gene have been reported in many countries, but the
prevalence of these two genes is relatively rare in China. That
could be explained that only one isolate carried the blaOXA−58
gene and no blaOXA−24 gene was detected in the CRAB isolates.
However, 10 isolates could detect none of the plasmid-mediated
OXA-carbapenemase genes including blaOXA−23, blaOXA−24 and
blaOXA−58, which indicated that these isolates might harbored
other resistant genes such as MBLs against carbapenem. These
data are consistent with other reports from China and other
countries (Turton et al., 2006; Woodford et al., 2006; Zavascki
et al., 2010; Tiwari et al., 2012a).
In the conventional PCR assay, the blaOXA−51−like gene could
not be ampliﬁed from seven clinical isolates. We thought that
the low bacterial contents and incorrect pathogen identiﬁcation
may account for the failure to amplify these samples. Thus, the
seven strains were analyzed for the presence of the blaOXA−51−like
gene by the LAMP method described here, yielding positive
results in each case, which was conﬁrmed using the Vitek 2
system. Our results showed that these clinical isolates were
actually A. baumannii. These results suggest that occasionally
the sensitivity of conventional PCR is not satisfactory and may
introduce errors into diagnostic test results.
Compared with traditional methods for pathogen diagnosis,
LAMP assays can generate results more easily and rapidly,
with high sensitivity and speciﬁcity (Notomi et al., 2000). The
LAMP reaction does not require temperature cycling, with just
a temperature-controlled water bath or a constant-temperature
environment being suﬃcient. LAMP primers are designed to
match four or six of the six or eight independent target-
sequence regions, so the speciﬁcity and sensitivity are enhanced
greatly. Under optimum conditions, the LAMP reaction can be
completed in 1 h. In this study, we described a LAMP assay based
on the blaOXA−51−like gene for detecting A. baumannii. This
LAMP method could detect the target DNA within 60 min at an
isothermal temperature of 65◦C. The detection limit of the LAMP
assay was 50 pg/μl, which was about 10-fold greater than that
of PCR. Furthermore, the LAMP method described here could
distinguish A. baumannii from A. nosocomialis (genospecies
13TU), A. pittii (genospecies 3), and the A. Baumannii complex
(A. baumannii, A. nosocomialis, A. pittii, and A. calcoaceticus).
Previously, there were two reports on the use of an A. baumannii
LAMP assay, based on targeting the 16S–23S rRNA intergenic
spacer sequence (Soo et al., 2013) and the conserved regions of
the pgaD gene of A. baumannii (Wang et al., 2013). However,
the former could not eﬀectively distinguish A. baumannii from
A. nosocomialis, and A. pittii, and the speciﬁcity of A. baumannii
LAMP assay of the latter was only 75%.
Conclusion
A rapid, sensitive, speciﬁc, and eﬀective LAMP assay was
established for the detection of A. baumannii. The LAMP assay
will be very useful for the rapid detection of pathogens in clinical
samples. Meanwhile, this report provides some therapeutic
recommendations for the treatment of A. baumannii infection
and a warning that the growing emergence of carbapenem-
resistant A. baumannii has led to an inadequacy of therapeutic
choices in treating MDR-AB infections among patients in
China. Our ﬁndings further emphasize that when investigating
outbreaks caused by carbapenem-resistant A. baumannii, both
the detection of carbapenemase-associated genes and PFGE are
needed.
Author Contributions
Puyuan Li and Wenkai Niu wrote the main manuscript text.
Puyuan Li, Huan Li, and Wei Liu prepared Figures 1–4. Leijing
Guo prepared Figure 5. Puyuan Li, Wenkai Niu, Hong Lei,
Xiangna Zhao, Dayang Zou, Xin Yuan, and Huiying Liu executed
the experiments. Changqing Bai and Jing Yuan helped conceive
the project and designed the experiments. All authors reviewed
the manuscript.
Funding
This project was supported by the Beijing Natural Science
Foundation (Grant No.7142118), a Translational Medicine
Project from the Academy of Military Medical Science in
2013, Mega-projects of Science and Technology Research of
China Grant 2013ZX10004-203, and Capital Characteristic Clinic
project of Beijing (Z121107001012127).
Acknowledgments
We thank the 309th Hospital of PLA and Institute of Disease
Control and Prevention, Academy of Military Medical Sciences
for kindly providing clinical isolates and reference strains. We
are grateful to Yin Xiuyun from the Department of Clinical
Laboratory of the 307th Hospital of PLA for performing the
collection of isolates. The analysis of PFGE by Wang Jian
from the Institute of Disease Control and Prevention, Academy
of Military Medical Sciences (Beijing, China) is gratefully
appreciated. We also thank Wei Xiao, Cui Qian, Yang Zhan, Yan
Xiabei, and Dong Derong for assistance during the course of this
research.
Frontiers in Microbiology | www.frontiersin.org 8 September 2015 | Volume 6 | Article 997
Li et al. LAMP-based detection of AB
References
Álvarez-Buylla, A., Culebras, E., and Picazo, J. J. (2012). Identiﬁcation of
Acinetobacter species: is Bruker biotyper MALDI-TOF mass spectrometry a
good alternative to molecular techniques? Infect. Genet. Evol. 12, 345–349. doi:
10.1016/j.meegid.2012.01.002
Antunes, L., Visca, P., and Towner, K. J. (2014). Acinetobacter baumannii:
evolution of a global pathogen. Pathog. Dis. 71, 292–301. doi: 10.1111/2049-
632X.12125
Chiang, M.-C., Kuo, S.-C., Chen, S.-J., Yang, S.-P., Lee, Y.-T., Chen, T.-L., et al.
(2012). Clinical characteristics and outcomes of bacteremia due to diﬀerent
genomic species of Acinetobacter baumannii complex in patients with solid
tumors. Infection 40, 19–26. doi: 10.1007/s15010-011-0187-4
Dijkshoorn, L., Nemec, A., and Seifert, H. (2007). An increasing threat in hospitals:
multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5, 939–951.
doi: 10.1038/nrmicro1789
Dinh, D. T., Le, M. T. Q., Vuong, C. D., Hasebe, F., and Morita, K.
(2011). An updated loop-mediated isothermal ampliﬁcation method for rapid
diagnosis of H5N1 Avian Inﬂuenza Viruses. Trop. Med. Health 39, 3–7. doi:
10.2149/tmh.2010-21
Farrell, D. J., Sader, H. S., Flamm, R. K., and Jones, R. N. (2014).
Ceftolozane/tazobactam activity tested against Gram-negative bacterial
isolates from hospitalised patients with pneumonia in US and European
medical centres (2012). Int. J. Antimicrob. Agents 43, 533–539. doi:
10.1016/j.ijantimicag.2014.01.032
Gales, A. C., Jones, R. N., and Sader, H. S. (2011). Contemporary activity of colistin
and polymyxin B against a worldwide collection of Gram-negative pathogens:
results from the SENTRY Antimicrobial Surveillance Program (2006–09).
J. Antimicrob. Chemother. 66, 2070–2074. doi: 10.1093/jac/dkr239
Golanbar, G. D., Lam, C. K., Chu, Y.-M., Cueva, C., Tan, S.W., Silva, I., et al. (2011).
Phenotypic and molecular characterization of Acinetobacter clinical isolates
obtained from inmates of California correctional facilities. J. Clin. Microbiol.
49, 2121–2131. doi: 10.1093/jac/dkr239
Gotoh, K., Nishimura, N., Takeuchi, S., Hattori, F., Horiba, K., Isaji, M.,
et al. (2013). Assessment of the loop-mediated isothermal ampliﬁcation assay
for rapid diagnosis of Mycoplasma pneumoniae in pediatric community-
acquired pneumonia. Jpn. J. Infect. Dis. 66, 539–542. doi: 10.1007/s10156-012-
0388-5
Janda, J. M., and Abbott, S. L. (2007). 16S rRNA gene sequencing for bacterial
identiﬁcation in the diagnostic laboratory: pluses, perils, and pitfalls. J. Clin.
Microbiol. 45, 2761–2764. doi: 10.1128/jcm.01228-07
Karageorgopoulos, D. E., and Falagas, M. E. (2008). Current control and treatment
of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8,
751–762. doi: 10.1016/S1473-3099(08)70279-2
Karah, N., Haldorsen, B., Hegstad, K., Simonsen, G. S., Sundsfjord, A.,
Samuelsen, Ø, et al. (2011). Species identiﬁcation and molecular
characterization of Acinetobacter spp. blood culture isolates from Norway.
J. Antimicrob. Chemother. 66, 738–744. doi: 10.1093/jac/dkq521
Kempf, M., and Rolain, J.-M. (2012). Emergence of resistance to carbapenems
in Acinetobacter baumannii in Europe: clinical impact and therapeutic
options. Int. J. Antimicrob. Agents 39, 105–114. doi: 10.1016/j.ijantimicag.2011.
10.004
Kumar, P., Pandya, D., Singh, N., Behera, D., Aggarwal, P., and Singh, S. (2014).
Loop-mediated isothermal ampliﬁcation assay for rapid and sensitive diagnosis
of tuberculosis. J. Infect. 69, 607–615. doi: 10.1016/j.jinf.2014.08.017
Kuo, H. Y., Chang, K. C., Kuo, J. W., Yueh, H. W., and Liou, M. L.
(2012). Imipenem: a potent inducer of multidrug resistance in
Acinetobacter baumannii. Int. J. Antimicrob. Agents 39, 33–38. doi:
10.1016/j.ijantimicag.2011.08.016
Lemos, E., de la Hoz, F., Einarson, T., McGhan, W., Quevedo, E., Castañeda, C.,
et al. (2014). Carbapenem resistance and mortality in patients with
Acinetobacter baumannii infection: systematic review and meta-analysis. Clin.
Microbiol. Infect. 20, 416–423. doi: 10.1111/1469-0691.12363
Nakauchi, M., Takayama, I., Takahashi, H., Tashiro, M., and Kageyama, T. (2014).
Development of a reverse transcription loop-mediated isothermal ampliﬁcation
assay for the rapid diagnosis of avian inﬂuenza A (H7N9) virus infection.
J. Virol. Methods 204, 101–104. doi: 10.1016/j.jviromet.2014.03.028
Nakauchi, M., Yoshikawa, T., Nakai, H., Sugata, K., Yoshikawa, A., Asano, Y.,
et al. (2011). Evaluation of reverse transcription loop-mediated isothermal
ampliﬁcation assays for rapid diagnosis of pandemic inﬂuenza A/H1N1 2009
virus. J. Med. Virol. 83, 10–15. doi: 10.1002/jmv.21934
Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T.,Watanabe, K., Amino, N.,
et al. (2000). Loop-mediated isothermal ampliﬁcation of DNA. Nucleic Acids
Res. 28, E63. doi: 10.1093/nar/28.12.e63
Olive, D. M., and Bean, P. (1999). Principles and applications of methods for
DNA-based typing of microbial organisms. J. Clin. Microbiol. 37, 1661–1669.
Park, Y. K., Jung, S.-I., Park, K.-H., Kim, S. H., and Ko, K. S. (2012). Characteristics
of carbapenem-resistant Acinetobacter spp. other than Acinetobacter
baumannii in South Korea. Int. J. Antimicrob. Agents 39, 81–85. doi:
10.1016/j.ijantimicag.2011.08.006
Peleg, A. Y., Seifert, H., and Paterson, D. L. (2008). Acinetobacter baumannii:
emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538–582. doi:
10.1128/CMR.00058-07
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., and
Bonomo, R. A. (2007). Global challenge of multidrug-resistant Acinetobacter
baumannii. Antimicrob. Agents Chemother. 51, 3471–3484. doi: 10.1128/aac.01
464-06
Pogue, J. M., Mann, T., Barber, K. E., and Kaye, K. S. (2013). Carbapenem-resistant
Acinetobacter baumannii: epidemiology, surveillance and management. Expert
Rev. Anti Infect. Ther. 11, 383–393. doi: 10.1586/eri.13.14
Poirel, L., Naas, T., and Nordmann, P. (2010). Diversity, epidemiology, and
genetics of class D beta-lactamases. Antimicrob. Agents Chemother. 54, 24–38.
doi: 10.1128/AAC.01512-08
Poirel, L., and Nordmann, P. (2006). Carbapenem resistance in Acinetobacter
baumannii: mechanisms and epidemiology.Clin.Microbiol. Infect. 12, 826–836.
doi: 10.1111/j.1469-0691.2006.01456.x
Poon, L. L., Leung, C. S., Tashiro, M., Chan, K. H., Wong, B. W., Yuen, K. Y.,
et al. (2004). Rapid detection of the severe acute respiratory syndrome (SARS)
coronavirus by a loop-mediated isothermal ampliﬁcation assay. Clin. Chem. 50,
1050–1052. doi: 10.1373/clinchem.2004.032011
Rhomberg, P. R., and Jones, R. N. (2009). Summary trends for the meropenem
yearly susceptibility test information collection program: a 10-year experience
in the United States (1999–2008).Diagn. Microbiol. Infect. Dis. 65, 414–426. doi:
10.1016/j.diagmicrobio.2009.08.020
Soo, P.-C., Tseng, C.-C., Ling, S.-R., Liou, M.-L., Liu, C.-C., Chao, H.-J., et al.
(2013). Rapid and sensitive detection of Acinetobacter baumannii using loop-
mediated isothermal ampliﬁcation. J. Microbiol. Methods 92, 197–200. doi:
10.1016/j.mimet.2012.11.020
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E.,
Persing, D. H., et al. (1995). Interpreting chromosomal DNA restriction
patterns produced by pulsed-ﬁeld gel electrophoresis: criteria for bacterial strain
typing. J. Clin. Microbiol. 33, 2233–2239.
Tiwari, V., Kapil, A., and Moganty, R. R. (2012a). Carbapenem-hydrolyzing
oxacillinase in high resistant strains of Acinetobacter baumannii isolated from
India.Microb. Pathog. 53, 81–86. doi: 10.1016/j.micpath.2012.05.004
Tiwari, V., Vashistt, J., Kapil, A., and Moganty, R. R. (2012b). Comparative
proteomics of inner membrane fraction from carbapenem-resistant
Acinetobacter baumannii with a reference strain. PLoS ONE 7:e39451.
doi: 10.1371/journal.pone.0039451
Tiwari, V., and Moganty, R. R. (2014). Conformational stability of OXA-
51 β-lactamase explains its role in carbapenem resistance of Acinetobacter
baumannii. J. Biomol. Struct. Dyn. 32, 1406–1420. doi: 10.1080/07391102.
2013.819789
Turton, J. F., Woodford, N., Glover, J., Yarde, S., Kaufmann, M. E., and Pitt, T. L.
(2006). Identiﬁcation of Acinetobacter baumannii by detection of the blaOXA-
51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 44,
2974–2976. doi: 10.1128/jcm.01021-06
Wang, Q., Zhou, Y., Li, S., Zhuo, C., Xu, S., Huang, L., et al. (2013). Real-
time ﬂuorescence loop mediated isothermal ampliﬁcation for the detection
of Acinetobacter baumannii. PLoS ONE 8:e66406. doi: 10.1371/journal.
pone.0066406
Woodford, N., Ellington, M. J., Coelho, J. M., Turton, J. F., Ward, M. E.,
Brown, S., et al. (2006). Multiplex PCR for genes encoding prevalent OXA
carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27, 351–353.
doi: 10.1016/j.ijantimicag.2006.01.004
Xi, H., Xu, Y., Zhu, D., Wang, F., Ni, Y., Sun, J., et al. (2012). CHINET 2010
surveillance of antibiotic resistance in Acinetobacter baumannii in China. Chin.
J. Infect. Chemother. 2, 006.
Frontiers in Microbiology | www.frontiersin.org 9 September 2015 | Volume 6 | Article 997
Li et al. LAMP-based detection of AB
Yan, Z.-Q., Shen, D.-X., Cao, J.-R., Chen, R., Wei, X., Liu, L.-P., et al.
(2010). Susceptibility patterns and molecular epidemiology of multidrug-
resistant Acinetobacter baumannii strains from three military hospitals in
China. I. J. Antimicrob. Agents 35, 269–273. doi: 10.1016/j.ijantimicag.2009.
10.016
Zarrilli, R., Pournaras, S., Giannouli, M., and Tsakris, A. (2013). Global evolution of
multidrug-resistant Acinetobacter baumannii clonal lineages. Int. J. Antimicrob.
Agents 41, 11–19. doi: 10.1016/j.ijantimicag.2012.09.008
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., and Gales, A. C. (2010). Multidrug-
resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance
mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther. 8,
71–93. doi: 10.1586/eri.09.108
Zeng, Y., Zhang, X., Nie, K., Ding, X., Ring, B. Z., Xu, L., et al. (2014).
Rapid quantitative detection of Human immunodeﬁciency virus type 1 by a
reverse transcription-loop-mediated isothermal ampliﬁcation assay. Gene 541,
123–128. doi: 10.1016/j.gene.2014.03.015
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Li, Niu, Li, Lei, Liu, Zhao, Guo, Zou, Yuan, Liu, Yuan and Bai.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 10 September 2015 | Volume 6 | Article 997
